[{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"d1c65fef-f151-4887-8cfe-4cca4bc9b521","acronym":"","url":"https://clinicaltrials.gov/study/NCT03282396","created_at":"2021-01-18T16:12:27.906Z","updated_at":"2024-07-02T16:35:08.356Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma","source_id_and_acronym":"NCT03282396","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-04-22"},{"id":"7c08cf87-45ad-4ad1-a2a0-cd9cc9ee571c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05203601","created_at":"2023-12-27T20:17:30.683Z","updated_at":"2024-07-02T16:35:25.088Z","phase":"Phase 1","brief_title":"A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.","source_id_and_acronym":"NCT05203601","lead_sponsor":"Shanghai Institute Of Biological Products","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4","pipe":" | ","alterations":" HER-2 overexpression","tags":["EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-12-27"},{"id":"e089e3f8-f160-47a9-a0b8-746650c303a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861050","created_at":"2023-05-16T17:06:41.960Z","updated_at":"2024-07-02T16:35:30.746Z","phase":"Phase 1/2","brief_title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05861050","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression","tags":["TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-11-01"},{"id":"c2135ca8-5593-472c-8d96-ec49b76272c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887726","created_at":"2023-06-05T15:07:18.697Z","updated_at":"2024-07-02T16:35:41.722Z","phase":"Phase 2","brief_title":"Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors","source_id_and_acronym":"NCT05887726","lead_sponsor":"Liaoning Tumor Hospital \u0026 Institute","biomarkers":" NOTCH2","pipe":"","alterations":" ","tags":["NOTCH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • epirubicin • vincristine • prednisone"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-07-27"},{"id":"6160affe-41bc-4a57-bb71-a5426702805e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990778","created_at":"2021-08-04T13:53:08.284Z","updated_at":"2024-07-02T16:36:15.692Z","phase":"Phase 2","brief_title":"Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04990778","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1 • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation","tags":["CCND1 • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • eprenetapopt (APR-246)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2022-03-10"},{"id":"1d17430c-1429-4991-b902-bba8b2ceee07","acronym":"","url":"https://clinicaltrials.gov/study/NCT02948855","created_at":"2021-01-18T14:28:59.625Z","updated_at":"2024-07-02T16:37:10.649Z","phase":"","brief_title":"Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases","source_id_and_acronym":"NCT02948855","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" NOTCH2","pipe":"","alterations":" ","tags":["NOTCH2"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-05-18"}]